98%
921
2 minutes
20
Background: The relationship between Alzheimer's disease (AD)-related pathology and cognition was not exactly consistent.
Objective: To explore whether the association between AD pathology and cognition can be moderated by frailty.
Methods: We included 1711 participants from the Alzheimer's Disease Neuroimaging Initiative database. Levels of cerebrospinal fluid amyloid-β, p-tau, and t-tau were identified for AD-related pathology based on the amyloid-β/tau/neurodegeneration (AT[N]) framework. Frailty was measured using a modified Frailty Index-11 (mFI-11). Regression and interaction models were utilized to assess the relationship among frailty, AT(N) profiles, and cognition. Moderation models analyzed the correlation between AT(N) profiles and cognition across three frailty levels. All analyses were corrected for age, sex, education, and APOEɛ4 status.
Results: In this study, frailty (odds ratio [OR] = 1.71, p < 0.001) and AT(N) profiles (OR = 2.00, p < 0.001) were independently associated with cognitive status. The model fit was improved when frailty was added to the model examining the relationship between AT(N) profiles and cognition (p < 0.001). There was a significant interaction between frailty and AT(N) profiles in relation to cognitive status (OR = 1.12, pinteraction = 0.028). Comparable results were obtained when Mini-Mental State Examination scores were utilized as the measure of cognitive performance. The association between AT(N) profiles and cognition was stronger with the levels of frailty.
Conclusions: Frailty may diminish patients' resilience to AD pathology and accelerate cognitive decline resulting from abnormal AD-related pathology. In summary, frailty contributes to elucidating the relationship between AD-related pathology and cognitive impairment.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3233/JAD-231489 | DOI Listing |
Clin Chem Lab Med
September 2025
Université Paris Cité, INSERM Unit UMR S-1144, Paris, France.
Objectives: Dysregulation of brain leptin signaling contributes to Alzheimer's disease (AD) pathophysiology, but plasma leptin may not accurately reflect central nervous system activity. This study examined the correlation between plasma and cerebrospinal fluid (CSF) leptin levels and their relationship with beta-amyloid (Aβ) and tau biomarkers.
Methods: Cross-sectional analysis of data from cognitively impaired patients from a tertiary memory clinic.
Sci Rep
August 2025
Center for Research and Memory Clinic, CITA-Alzheimer Foundation, Donostia-San Sebastián, 20009, Spain.
Early identification of Alzheimer's disease (AD) pathology is essential for timely intervention, particularly in primary care. We evaluated the diagnostic performance of a scalable, multimodal framework in a real-world, population-based cohort. A total of 277 community-dwelling individuals aged ≥ 60 years from the STOP-ALZHEIMER DEBA study (Basque Country, Spain) underwent brief cognitive screening (MMSE, M@T, Fototest, AD8) with optimized cut-offs, along with clinical risk assessment.
View Article and Find Full Text PDFStem Cell Res Ther
July 2025
Department of Genetic Medicine, Dongguan Children's Hospital Affiliated to Guangdong Medical University, Dongguan, China.
Background: Type 1 diabetes mellitus (T1DM) is a chronic autoimmune disease characterized by absolute insulin (INS) deficiency. As key components of the immune system, macrophages play critical roles in T1DM-associated pancreatic β-cell damage and multiorgan inflammatory injuries. Exosomes derived from human umbilical cord mesenchymal stem cells (hucMSC-EXOs) have emerged as promising therapeutic agents for immune-related disorders due to their immunomodulatory properties and favorable safety profile.
View Article and Find Full Text PDFAlzheimers Res Ther
July 2025
Paris-Cité University, Inserm U1144, Paris, France.
Background: Anticholinergic medications are widely prescribed to older adults and are linked to increased mortality and cognitive decline. Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD)-amyloid and tau-are strong prognostic indicators in neurocognitive disorders (NCD). However, it remains unclear whether anticholinergic burden amplifies mortality risk depending on CSF biomarker profiles in cognitively impaired individuals.
View Article and Find Full Text PDFTransl Psychiatry
July 2025
Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.
Progranulin (PGRN) and soluble triggering receptor expressed on myeloid cells-2 (sTREM2) are emerging biomarkers of Alzheimer's disease (AD). This study explores the roles of their interplay in modulating amyloid pathology. We analyzed data from 905 participants (mean age = 62.
View Article and Find Full Text PDF